MX394244B - Metodos, composiciones, y kits para tratar y/o prevenir un efecto secundario asociado con radiacion y/o exposicion a quimioterapia - Google Patents

Metodos, composiciones, y kits para tratar y/o prevenir un efecto secundario asociado con radiacion y/o exposicion a quimioterapia

Info

Publication number
MX394244B
MX394244B MX2019010931A MX2019010931A MX394244B MX 394244 B MX394244 B MX 394244B MX 2019010931 A MX2019010931 A MX 2019010931A MX 2019010931 A MX2019010931 A MX 2019010931A MX 394244 B MX394244 B MX 394244B
Authority
MX
Mexico
Prior art keywords
kits
compositions
methods
treating
preventing
Prior art date
Application number
MX2019010931A
Other languages
English (en)
Other versions
MX2019010931A (es
Inventor
Ines Batinic-Haberle
James D Crapo
Kathleen Ashcraft
Mark Dewhirst
Original Assignee
Biomimetix Jv Llc
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomimetix Jv Llc, Univ Duke filed Critical Biomimetix Jv Llc
Publication of MX2019010931A publication Critical patent/MX2019010931A/es
Publication of MX394244B publication Critical patent/MX394244B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen en la presente metodos, composiciones, y kits para tratar y/o prevenir en un sujeto uno o mas efectos secundarios asociados con radiacion y/o exposicion a quimioterapia,incluyendo metodos, composiciones y kits que incluyen un agente activo a una baja dosis; en algunas modalidades, se proporcionan metodos, composiciones, y kits para tratar y/o prevenir daño al tejido en un sujeto, incluyendo metodos, composiciones y kits que incluyen un agente activo a una dosis baja.
MX2019010931A 2017-04-04 2018-04-04 Metodos, composiciones, y kits para tratar y/o prevenir un efecto secundario asociado con radiacion y/o exposicion a quimioterapia MX394244B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762481460P 2017-04-04 2017-04-04
PCT/US2018/026002 WO2018187411A1 (en) 2017-04-04 2018-04-04 Methods, compositions, and kits for treating and/or preventing a side effect associated with radiation and/or chemotherapy exposure

Publications (2)

Publication Number Publication Date
MX2019010931A MX2019010931A (es) 2020-01-21
MX394244B true MX394244B (es) 2025-03-24

Family

ID=63712315

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010931A MX394244B (es) 2017-04-04 2018-04-04 Metodos, composiciones, y kits para tratar y/o prevenir un efecto secundario asociado con radiacion y/o exposicion a quimioterapia

Country Status (10)

Country Link
US (3) US11285162B2 (es)
EP (2) EP3606614B1 (es)
JP (1) JP7333560B2 (es)
KR (2) KR20190130654A (es)
CN (1) CN110621377A (es)
CA (1) CA3052875A1 (es)
ES (1) ES3033013T3 (es)
MX (1) MX394244B (es)
PL (1) PL3606614T3 (es)
WO (1) WO2018187411A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX394244B (es) * 2017-04-04 2025-03-24 Biomimetix Jv Llc Metodos, composiciones, y kits para tratar y/o prevenir un efecto secundario asociado con radiacion y/o exposicion a quimioterapia
CN111011309A (zh) * 2020-03-03 2020-04-17 江西中医药大学 一种化疗药物致大鼠口腔溃疡模型建立方法及其应用
CN115838797B (zh) * 2022-11-22 2025-03-14 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种与放化疗引起的听力损伤相关的snp标志物及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6448239B1 (en) 1999-06-03 2002-09-10 Trustees Of Princeton University Peroxynitrite decomposition catalysts and methods of use thereof
US20030050297A1 (en) 2001-01-19 2003-03-13 Crapo James D. Cancer therapy
EP1718201B1 (en) 2004-02-09 2016-09-14 Duke University Substituted porphyrins
CN101235036A (zh) * 2007-02-02 2008-08-06 济南赛文医药技术有限公司 一类卟啉衍生物及其作为小分子抗氧化剂的应用
WO2010080881A1 (en) 2009-01-07 2010-07-15 Duke University Substituted porphyrins
WO2015034778A1 (en) 2013-09-03 2015-03-12 Biomimetix J.V., Llc Methods of treating erectile dysfunction
US10080759B2 (en) * 2014-01-22 2018-09-25 Duke University Methods of treating pruritus
US10064871B2 (en) * 2014-01-22 2018-09-04 Biomimetix Jv, Llc Methods of treating skin disorders
EP3558902A4 (en) * 2016-12-20 2020-06-24 Duke University METHOD FOR PRODUCING PHARMACEUTICAL COMPOUNDS WITH SUBSTITUTED PORPHYRINE AND COMPOSITIONS
MX394244B (es) * 2017-04-04 2025-03-24 Biomimetix Jv Llc Metodos, composiciones, y kits para tratar y/o prevenir un efecto secundario asociado con radiacion y/o exposicion a quimioterapia
WO2018237249A1 (en) * 2017-06-22 2018-12-27 Biomimetix Jv, Llc Methods, compositions, and kits for treating inflammatory skin conditions
EP3687551A4 (en) 2017-09-29 2021-06-23 Duke University FLUORUSUBSTITUTED PORPHYRINE COMPOUNDS, THESE PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR MANUFACTURE AND USE

Also Published As

Publication number Publication date
ES3033013T3 (en) 2025-07-29
EP3606614A4 (en) 2020-10-28
PL3606614T3 (pl) 2025-09-15
US20220193090A1 (en) 2022-06-23
EP3606614B1 (en) 2025-05-21
WO2018187411A1 (en) 2018-10-11
EP3606614A1 (en) 2020-02-12
JP7333560B2 (ja) 2023-08-25
CA3052875A1 (en) 2018-10-11
MX2019010931A (es) 2020-01-21
KR20190130654A (ko) 2019-11-22
US12171769B2 (en) 2024-12-24
JP2020515630A (ja) 2020-05-28
CN110621377A (zh) 2019-12-27
EP3606614C0 (en) 2025-05-21
EP4603096A1 (en) 2025-08-20
KR20240116576A (ko) 2024-07-29
US20250041314A1 (en) 2025-02-06
US20210106594A1 (en) 2021-04-15
US11285162B2 (en) 2022-03-29

Similar Documents

Publication Publication Date Title
PH12020551923A1 (en) Methods and compositions for treating cancer
PH12021500004A1 (en) Pd-1/pd-l1 inhibitors
PH12020551244A1 (en) Pd-1/pd-l1 inhibitors
PH12019501575A1 (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFá1 INHIBITORS AND USE THEREOF
PH12020550936A1 (en) Combination drug including tlr7 agonist
MX2018002723A (es) Macrociclicos peptidomimeticos y usos de los mismos.
MX2022001075A (es) Compuestos para usarse en el tratamiento de cancer de mama que expresa el receptor de androgenos (ar+).
EA201591674A1 (ru) Противораковые вакцины и способы лечения с их применением
MX2018008190A (es) Sistemas y metodos para la administracion transdermica a largo plazo.
MX2019008701A (es) Terapia de combinacion que involucra compuestos macrociclicos de diarilo.
MX2019009753A (es) Composicion y metodos para prevenir lesion por radiacion y promover la regeneracion de tejidos.
MX2015013177A (es) Combinacion de tratamientod de cancer usando microarns e inhibidores de egfr-tki.
MX2018007266A (es) Combinaciones para el tratamiento del cancer.
MX2020012163A (es) Composiciones de proteccion solar con resistencia al agua mejorada de agentes activos de proteccion solar de rayos ultravioleta (uva).
MX2020000467A (es) Compuestos retinoides y rexinoides inmunomoduladores en combinacion con inmunomoduladores para inmunoterapia contra cancer.
CL2017001964A1 (es) Encapsulado de agentes activos de alta potencia.
MX2023000549A (es) Combinaciones para el tratamiento de neoplasias usando localizacion de celulas quiescentes e inhibidores de egfr.
UY35803A (es) Recubrimiento de alginato para tratamiento de esquejes
MX394244B (es) Metodos, composiciones, y kits para tratar y/o prevenir un efecto secundario asociado con radiacion y/o exposicion a quimioterapia
WO2017019721A3 (en) Combinations of ezh2 inhibitors with further agents for use in the treatment of cancer
WO2016127123A3 (en) Compounds and methods for preventing or treating sensory hair cell death
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
MX2019007041A (es) Metodos y composiciones para tratar la enfermedad de parkinson.
WO2020086954A3 (en) Treatments for charcot-marie-tooth disease